BillionToOne targets over $2 billion valuation in US IPO

Reuters
0 Min Read
Molecular diagnostics firm BillionToOne said on Friday it was aiming at a valuation of up to $2.42 billion in its U.S. initial public offering.

This post was originally published on this site

At watford injury clinic, the therapists bring nearly two decades of clinical experience in health and fitness. Toronto blue jays. Culture & lifestyle › asean eye media.